158 related articles for article (PubMed ID: 10408702)
1. Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits.
Verheul HM; Panigrahy D; Yuan J; D'Amato RJ
Br J Cancer; 1999 Jan; 79(1):114-8. PubMed ID: 10408702
[TBL] [Abstract][Full Text] [Related]
2. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization.
Kenyon BM; Browne F; D'Amato RJ
Exp Eye Res; 1997 Jun; 64(6):971-8. PubMed ID: 9301478
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor.
Kruse FE; Joussen AM; Rohrschneider K; Becker MD; Völcker HE
Graefes Arch Clin Exp Ophthalmol; 1998 Jun; 236(6):461-6. PubMed ID: 9646092
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice.
Kotoh T; Dhar DK; Masunaga R; Tabara H; Tachibana M; Kubota H; Kohno H; Nagasue N
Surgery; 1999 May; 125(5):536-44. PubMed ID: 10330943
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro.
Moreira AL; Friedlander DR; Shif B; Kaplan G; Zagzag D
J Neurooncol; 1999 Jun; 43(2):109-14. PubMed ID: 10533722
[TBL] [Abstract][Full Text] [Related]
6. Thalidomide is an inhibitor of angiogenesis.
D'Amato RJ; Loughnan MS; Flynn E; Folkman J
Proc Natl Acad Sci U S A; 1994 Apr; 91(9):4082-5. PubMed ID: 7513432
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
Joseph IB; Isaacs JT
Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
[TBL] [Abstract][Full Text] [Related]
8. Effect of thalidomide on colorectal cancer liver metastases in CBA mice.
Daruwalla J; Nikfarjam M; Malcontenti-Wilson C; Muralidharan V; Christophi C
J Surg Oncol; 2005 Aug; 91(2):134-40. PubMed ID: 16028287
[TBL] [Abstract][Full Text] [Related]
9. Differential suppression of vascular permeability and corneal angiogenesis by nonsteroidal anti-inflammatory drugs.
Pakneshan P; Birsner AE; Adini I; Becker CM; D'Amato RJ
Invest Ophthalmol Vis Sci; 2008 Sep; 49(9):3909-13. PubMed ID: 18487370
[TBL] [Abstract][Full Text] [Related]
10. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide attenuates mammary cancer associated-inflammation, angiogenesis and tumor growth in mice.
Maria de Souza C; Fonseca de Carvalho L; da Silva Vieira T; Cândida Araújo E Silva A; Teresa Paz Lopes M; Alves Neves Diniz Ferreira M; Passos Andrade S; Dantas Cassali G
Biomed Pharmacother; 2012 Oct; 66(7):491-8. PubMed ID: 22705333
[TBL] [Abstract][Full Text] [Related]
12. IFN-alpha2b and thalidomide synergistically inhibit tumor-induced angiogenesis.
Bauer JA; Morrison BH; Grane RW; Jacobs BS; Borden EC; Lindner DJ
J Interferon Cytokine Res; 2003 Jan; 23(1):3-10. PubMed ID: 12639293
[TBL] [Abstract][Full Text] [Related]
13. Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization.
Castro MR; Lutz D; Edelman JL
Exp Eye Res; 2004 Aug; 79(2):275-85. PubMed ID: 15325574
[TBL] [Abstract][Full Text] [Related]
14. Effect of thalidomide and structurally related compounds on corneal angiogenesis is comparable to their teratological potency.
Joussen AM; Germann T; Kirchhof B
Graefes Arch Clin Exp Ophthalmol; 1999 Dec; 237(12):952-61. PubMed ID: 10654163
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic activity of tumor necrosis factor-alpha production regulators derived from thalidomide.
Shimazawa R; Miyachi H; Takayama H; Kuroda K; Kato F; Kato M; Hashimoto Y
Biol Pharm Bull; 1999 Feb; 22(2):224-6. PubMed ID: 10077449
[TBL] [Abstract][Full Text] [Related]
16. The inhibitory effects of recombinant plasminogen kringle 1-3 on the neovascularization of rabbit cornea induced by angiogenin, bFGF, and VEGF.
Kim JH; Kim JC; Shin SH; Chang SI; Lee HS; Chung SI
Exp Mol Med; 1999 Dec; 31(4):203-9. PubMed ID: 10630375
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis.
Du GJ; Lin HH; Xu QT; Wang MW
Vascul Pharmacol; 2005 Aug; 43(2):112-9. PubMed ID: 15982930
[TBL] [Abstract][Full Text] [Related]
18. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis).
Azar DT
Trans Am Ophthalmol Soc; 2006; 104():264-302. PubMed ID: 17471348
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor effect of thalidomide and paclitaxel on hepatocellular carcinoma in nude mice.
Zhang ZL; Liu ZS; Sun Q
Chin Med J (Engl); 2005 Oct; 118(20):1688-94. PubMed ID: 16313753
[TBL] [Abstract][Full Text] [Related]
20. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.
Kuba K; Matsumoto K; Date K; Shimura H; Tanaka M; Nakamura T
Cancer Res; 2000 Dec; 60(23):6737-43. PubMed ID: 11118060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
